Nano co-delivery system: Albumin nanoparticles co-loaded gemcitabine and MEK inhibitors, increasing the tumor/plasma drug concentration ratio to 9.8:1, significantly inhibiting the activation of the MAPK pathway (Liu D. et al., 2024). The gene discussed is ALB; the disease is neoplasm.